Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Guess that proves my point

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Feb 12, 2022 1:55pm

327 Views

Post# 34423405

Guess that proves my point

"but as you can see everytime I post something of substance here , I get lots of reads but only the usual 3 or 4 goons speak up. One actually "tried" to be slanderous against an NO producer. Then I see my words over on the 2 private insider's sites, often misquoted and mocked without me having a voice there. So no I don't think anyone here , that posts really cares about N.O....."

<< Previous

Bullboard Posts

Next >>

Cybin launches new program phase to treat Major Depressive Disorder